Archive: Company News
Company News: Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing
– Successful completion of GEAR asset and know how transfer from Siemens to Curetis
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company has established Ares Genetics GmbH, a wholly owned subsidiary of Curetis GmbH. Ares Genetics builds on GEAR GEnetic Antibiotic Resistance and Susceptibility Database and associated assets recently acquired for Siemens.
Company News: Curetis to Publish its Annual Results 2016 on April 12, 2017
– Company to host earnings conference call and webcast
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2016 financial results on April 12, 2017. In addition, the Company will host a public earnings conference call and webcast on April 12, 2017, at 03:00 pm CET / 09:00am EST to present the financial results of 2016, highlight the most important events and provide an outlook for 2017.
Company News: Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company will attend several major industry conferences in the second quarter of 2017. The respective presentations will be made available on the company’s website.
Read more…
Company News: Provecs Medical closes immuno-oncology collaboration with Medac
— Joint development of Immunalon® in urinary bladder cancer
Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the closing of a partnership with oncology pharma company Medac Gesellschaft für klinische Spezialpräparate mbH. The partners aim to develop, manufacture and market Provec’s cancer immunotherapy lead product Immunalon® for the treatment of urinary bladder cancer.